Preconditioning with StemRegenin 1 enhances human adipose stromal/stem cells proliferation, migration, and protection against antimycin A.
Zhao J., Yu B., Fradette J., Annabi B., Petropavlovskaia M., Eliopoulos N.
Laboratory Study, published in Mol Ther Methods Clin Dev (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Mol Ther Methods Clin Dev (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41257286
- DOI
- 10.1016/j.omtm.2025.101616
Abstract (original English)
Adipose-derived stromal/stem cells (ASCs) are promising for the treatment of many diseases, including tissue injury or degeneration associated with serious disease and high morbidity. The extent of cell therapy effectiveness, however, may be limited by the lower survival of implanted cells in environments of tissue damage. Therefore, strategies to improve cell survival are important, such as by pretreating/preconditioning cells with a beneficial agent. We investigated the pretreatment of human ASCs (hASCs) with StemRegenin 1 (SR1), a purine derivative used in clinical protocols for in vitro hematopoietic stem/progenitor cell expansion. We pretreated hASCs with SR1 and analyzed the resulting cells (SR1-hASCs) as compared to non-treated cells (NT-hASCs). We noted that treatment with SR1 significantly increased the proliferation and migration of hASCs, as well as their secretion of paracrine factors of interest, and did not affect their cell differentiation capacity. Furthermore, when these SR1-hASCs were subsequently exposed to antimycin A, a mitochondrial respiratory chain inhibitor, they showed significantly higher antioxidative, anti-apoptotic, and pro-survival abilities as compared to NT-hASCs. Since oxidative stress and other harsh environments result from tissue damage, our results support that the preconditioning of hASCs with SR1 may enhance their protective, reparative,
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.